Statera Biopharma, Inc. (STAB)

NASDAQ: STAB · IEX Real-Time Price · USD
0.261
+0.006 (2.23%)
Aug 12, 2022 11:42 AM EDT - Market open
2.23%
Market Cap 13.06M
Revenue (ttm) 236,519
Net Income (ttm) -14.61M
Shares Out 50.02M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 59,985
Open 0.270
Previous Close 0.255
Day's Range 0.255 - 0.270
52-Week Range 0.200 - 4.660
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 15, 2022

About STAB

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical pro... [Read more...]

Industry Biotechnology
IPO Date Jul 21, 2006
Employees 18
Stock Exchange NASDAQ
Ticker Symbol STAB
Full Company Profile

Financial Performance

In 2020, STAB's revenue was $262,942, a decrease of -76.38% compared to the previous year's $1.11 million. Losses were -$2.40 million, -9.39% less than in 2019.

Financial Statements

News

Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapie...

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restora...

Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing R...

Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders Statera expects to acquire option to license Lay Sciences products for respiratory & gastr...

Why Is Statera Biopharma (STAB) Stock Up Today?

Today, investors in STAB stock have received a big boost as a a result of a signed commercialization agreement. The post Why Is Statera Biopharma (STAB) Stock Up Today?

Why Are Statera Biopharma Shares Surging Today

Statera Biopharma Inc (NASDAQ: STAB) has entered into a non-binding term sheet with Immune Therapeutics Inc (OTC: IMUN) to sell its naltrexone and met-enkephalin rights. The transaction is contingent up...

Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immu...

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing

FORT COLLINS, Colo., April 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune resto...

Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod

FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune resto...

Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, fro...

Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional preclinical programs advancing in neutropenia and anemia in cancer patients WEXFORD, ...

Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

Live Conference Call and Webcast at 5:30 p.m. ET

Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering

FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune...

Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune...

CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune...

Statera Biopharma Announces Proposed Underwritten Public Offering

FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune...

Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021

FORT COLLINS, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune...

Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform

In collaboration with MolSoft, ImQuest, a Statera company, is investigating new, optimized compositions incorporating desirable elements of STAT-200

CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-H...

Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19) Statera developing STAT-205 as novel therapy for immune modulati...

Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19) Statera developing STAT-205 as novel therapy for immune modulati...

Statera Biopharma Announces Changes to Board of Directors

—Satish Chandran of Lays Sciences and Physis Pharma, Inc. to join Board of Directors as Steve Barbarick transitions to advisory role—

Statera Biopharma Announces Preliminary Revenue and Financial Results of Fiscal Year ‘21

FORT COLLINS, Colo., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune ...

Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatri...

STAT-201 is being developed as a novel, immune-modulation therapy  for treating Crohn's Disease

Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering

FORT COLLINS, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune ...

Statera Biopharma Shares Tumble After Raising $2M Via Equity

Statera Biopharma Inc STAB has announced a registered direct offering of $2 million common stock and warrants. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Statera Biopharma Announces Pricing of $2.0 Million Registered Direct Offering

FORT COLLINS, Colo., Feb. 06, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune ...

Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn's D...

Company developing STAT-201 as a novel therapy for immune modulation in treating pediatric patients with Crohn's Disease Company developing STAT-201 as a novel therapy for immune modulation in treating ...